Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study

• Published in: Clinical research in cardiology 2020-08, Vol.109 (8), p.967-977
• Main Authors: Lombardi, Carlo Mario, Ferreira, João Pedro, Carubelli, Valentina, Anker, Stefan D., Cleland, John G., Dickstein, Kenneth, Filippatos, Gerasimos, Lang, Chim C., Ng, Leong L., Ponikowski, Piotr, Samani, Nilesh J., van Veldhuisen, Dirk J., Zannad, Faiez, Voors, Adriaan, Metra, Marco
• Format: Article
• Language: English
• Subjects: Cardiology; Clinical trials; Congestive heart failure; Diabetes mellitus; Heart failure; Hypertension; Kidney diseases; Medicine; Medicine & Public Health; Original Paper; Patients; Signs and symptoms; Titration
• ISSN: 1861-0684; 1861-0692
• DOI: 10.1007/s00392-019-01588-7

Background Geographical differences may impact the treatment of heart failure (HF) and the results of clinical trials. We have investigated the differences between geographical areas across Europe in the BIOSTAT-CHF program. Methods Patients with worsening HF enrolled in BIOSTAT-CHF were subdivided, according to the European geographical areas, into those from Northern countries (The Netherlands, Norway, Sweden, UK), Central countries (Germany, Poland, Serbia, Slovenia), and Mediterranean countries (France, Greece, Italy). Patients were compared for baseline characteristics, treatment, and outcomes. The primary endpoint was a composite of all-cause mortality or HF hospitalization. Results Among 2516 patients enrolled in BIOSTAT-CHF, 814 (32.3%) were from Northern European centers, 816 (32.4%) from Central European centers, and 886 (35.2%) from Mediterranean centers. Patients from Northern European centers were older, had more severe signs and symptoms of HF, and with lower incidence of non-cardiac comorbidities such as chronic kidney dysfunction, diabetes and, hypertension, compared to those from the Central and Mediterranean centers. Patients receiving ≥ 50% of the target dose of both ACE-I/ARB after the up-titration phase were higher in the Northern European centers compared with the other regions (60% versus 58.7% in the Central European centers and 46.5% in the Mediterranean ones; p   0.05). Conclusion The BIOSTAT-CHF study showed significant differences in the clinical features, treatment and prognosis in European patients with HF. Patients from the Mediterranean centers less often had the HF treatments up-titrated; however, the treatment up-titration benefited patients irrespective of their geographical region and should be part of the “default” clinical practice.